Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed First North Stockholm
11/11/2019 11/12/2019 11/13/2019 11/14/2019 11/15/2019 Date
12.15(c) 11.75(c) 11.4(c) 11.4(c) 11.4(c) Last
44 588 36 160 64 597 72 244 24 926 Volume
+0.41% -3.29% -2.98% 0.00% 0.00% Change
More quotes
Financials (SEK)
Sales 2020 4,60 M
EBIT 2020 -29,0 M
Net income 2020 -36,0 M
Finance 2020 26,0 M
Yield 2020 -
Sales 2021 21,3 M
EBIT 2021 -12,0 M
Net income 2021 -5,00 M
Finance 2021 15,5 M
Yield 2021 -
P/E ratio 2020 -7,40x
P/E ratio 2021 -51,8x
EV / Sales2020 52,8x
EV / Sales2021 11,9x
Capitalization 269 M
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test,... 
More about the company
Latest news on BIOVICA INTERNATIONAL AB (
11/15BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
AQ
10/25BIOVICA ISO 13485 : 2016 certificate renewal
AQ
10/03BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
AQ
09/18BIOVICA INTERNATIONAL : DiviTum® Included in New U.S. Cancer Study
AQ
09/18BIOVICA INTERNATIONAL : invites to telephone conference/audiocast
AQ
09/17BIOVICA INTERNATIONAL : New scientific publication focuses on DiviTum® and highl..
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (

- No features available -

More news
Sector news : Bio Diagnostics & Testing
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Bio Diagnostics & Testing
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 23,10  SEK
Last Close Price 11,40  SEK
Spread / Highest target 103%
Spread / Average Target 103%
Spread / Lowest Target 103%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors